- Conditions
- Influenza Immunization, Healthy Volunteers
- Interventions
- Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 84 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Bardstown, Kentucky • Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 154
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Case Formulation plus Cognitive Processing Therapy, Cognitive Processing Therapy
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Honolulu, Hawaii • New Orleans, Louisiana + 5 more
- Conditions
- Bioequivalence
- Interventions
- Pharmaceutical-lipid aspirin (PL-ASA)
- Drug
- Lead sponsor
- PLx Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Multiple Myeloma
- Interventions
- Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2014
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Healthy Volunteer
- Interventions
- AI-1000 G2, PFS-NSD, Tocilizumab
- Device · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 189 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- Lenexa, Kansas • Marlton, New Jersey • Salt Lake City, Utah
- Conditions
- Influenza
- Interventions
- Investigational H7N1 vaccine GSK2789869A, Investigational H7N1 vaccine GSK2789868A, Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 21 Years to 64 Years
- Enrollment
- 427 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 6
- States / cities
- Miami, Florida • Stockbridge, Georgia • Las Vegas, Nevada + 3 more
- Conditions
- Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
- Interventions
- Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 8
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 4 more
- Conditions
- Anesthesia, Local
- Interventions
- AG-920, Placebo
- Drug
- Lead sponsor
- American Genomics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- McAllen, Texas
- Conditions
- Raynaud's Disease
- Interventions
- Nitroglycerin
- Drug
- Lead sponsor
- MediQuest Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Albany, New York
- Conditions
- Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
- Interventions
- alisertib, methotrexate, cisplatin, carboplatin, cyclophosphamide, etoposide, topotecan, vincristine, Surgical resection, Radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 9
- States / cities
- Palo Alto, California • San Diego, California • Aurora, Colorado + 6 more
- Conditions
- Dentin Sensitivity
- Interventions
- Experimental Mouth Rinse 12027-033, Placebo Mouth Rinse
- Device · Other
- Lead sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 2
- States / cities
- Fort Wayne, Indiana • Las Vegas, Nevada
- Conditions
- Schizophrenia Prodrome
- Interventions
- Glycine, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 13 Years to 35 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
- Interventions
- Liposomal Cyclosporine A, Standard of Care
- Drug
- Lead sponsor
- Zambon SpA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
- Interventions
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
- Drug · Procedure · Other
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Compound AC220
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 20
- States / cities
- San Francisco, California • Chicago, Illinois • Indianapolis, Indiana + 14 more
- Conditions
- Influenza
- Interventions
- Fluzone Quadrivalent vaccine, No Preservative
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 35 Months
- Enrollment
- 1,950 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Harrisburg, Arkansas • Downey, California + 28 more
- Conditions
- Healthy
- Interventions
- Embibatinib, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine
- Drug
- Lead sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Millcreek, Utah
- Conditions
- Acne
- Interventions
- Skin Nutraceutical Supplement, Placebo pill
- Dietary Supplement · Other
- Lead sponsor
- Nutraceutical Wellness Inc.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
- Conditions
- Acute Myeloid Leukemia
- Interventions
- CPX-351, Gemtuzumab Ozogamicin
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy, Hepatitis C, Chronic
- Interventions
- TG-2349, placebo
- Drug
- Lead sponsor
- TaiGen Biotechnology Co., Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Viral Pneumonia
- Interventions
- SNG001, Placebo
- Drug
- Lead sponsor
- Synairgen Research Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Detroit, Michigan + 2 more
- Conditions
- COVID-19
- Interventions
- Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 BA.4/5 bivalent, XBB.1.5-adapted vaccinated
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Healthy
- Interventions
- Azithromycin 600 mg Tablet, Zithromax® 600 mg Tablet
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Solid Tumor
- Interventions
- Sirolimus, Cyclophosphamide, Etoposide, Celecoxib
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more